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ABSTRACT
This meeting held at the University of Barcelona in March 2017, brought together 
scientists and clinicians worldwide to discuss current and future clinico-biological 
implications of intratumoral heterogeneity (ITH) and subclonal evolution in cancer 
diagnosis, patient stratification, and treatment resistance in diagnosis, treatment 
and follow-up. There was consensus that both longitudinal and tumor multi-region 
studies in matched samples are needed to better understand the dynamics of ITH. The 
contribution of the epigenome and microenvironment to ITH and subclone evolution 
remains understudied. It was recommended to combine computational, pathology 
and imaging tools to study the role of the microenvironment in subclone selection/
evolution.
INTRODUCTION
Dr. Pablo Menéndez, an ICREA professor and the 
Scientific Director of the Campus Clinic Josep Carreras 
Leukemia Research Institute, opened the meeting by 
welcoming everyone and acknowledging the funding 
bodies for their efforts to “reprogram” Barcelona into a 
scientific and clinical hub for hemato-oncology research. 
Cancers evolve through a dynamic process of clonal 
expansion, genetic diversification and clonal selection 
within the adaptive landscapes of tissue ecosystems. The 
highly variable and dynamic patterns of genetic diversity 
results in a complex intratumor heterogeneity (ITH), the 
central topic of the meeting. While therapeutic intervention 
may destroy specific cancer clones, it inadvertently 
provides a selective pressure for the expansion of other, 
genetically distinct, clones. This intraclonal cancer 
evolution has been attributed to Darwinian evolutionary 
principles, which may lead to therapeutic failure through 
the ability of specific clones to become therapy resistant. 
ITH and clonal evolution are expected to have 
significant impact on cancer biology, and the clinical 
significance of ITH and its temporal evolution and 
dynamics in response to therapy is anticipated to become 
increasingly relevant to the way we diagnose, treat and 
follow-up cancer patients. Emerging questions posed 
from the outset were: i) Will we ever achieve complete 
responses using monotherapy, or will polytherapy be 
necessary to manage ITH-mediated malignancy?; ii) Is it 
crucial to identify the bona fide initiating/driver oncogenic 
event to develop targeted therapeutic strategies?; iii) Does 
patient stratification at diagnosis need to be revisited?; iv) 
Should we apply this emerging knowledge to the way we 
measure minimal residual disease (MRD) in follow-up 
studies?, etc. 
AN EVOLUTIONARY PERSPECTIVE OF 
CANCER
The session highlighted the Darwinian branched 
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model as the current schema to explain cancer evolution 
and subclone emergence and diversification from the 
tumor trunk. The lineal evolution model with sequential 
acquisition of mutations was disregarded [1]. Dr. David 
Posada (University of Vigo, Spain) described tumor 
phylogeography and spatial distribution of genetic 
lineages, contending that ITH should be studied using 
population genetics techniques. He employed Clomial 
(Bioconductor), a generative binomial model, to analyze 
next generation sequencing (NGS) data, and demonstrated 
how statistical phylogeographic inference from multiple 
tumor regions can aid to understand the modo and tempo 
of evolution in colorectal tumors. Dr. Andrea Sottoriva 
(Institute of Cancer Research, Sutton, UK) introduced 
the concept of neutral evolution to reflect selection-free 
evolution, where all tumor cells have equal growth rate. 
He highlighted the importance of understanding ITH in the 
absence of mutations and selection to distinguish between 
functional and non-functional heterogeneity [2]. Methods 
to infer the role of natural selection within tumors were 
presented by Dr. Christina Curtis (Stanford University, 
CA, USA). By simulating spatial tumor growth under 
different evolutionary modes and examining patterns 
of between-region subclonal genetic divergence from 
multi-region sequencing data, her group showed that 
it is feasible to distinguish tumors with strong positive 
subclonal selection from those evolving neutrally or 
under weak selection. All speakers raised the challenges 
of automatic frequency-based methods to directly estimate 
the evolutionary trajectories from bulk sequencing data.
MOLECULAR DIAGNOSIS OF ITH
The session discussed how to diagnose ITH using 
NGS or mass-spectometry-based cytometry approaches. 
In the context of hematopoietic stem cell (HSC) 
heterogeneity, Dr. David Kent (Cambridge Institute for 
Biomedical Research, Cambridge, UK) discussed the 
impact that the acquisition order of mutations (TET2 and 
JAK2V617F) has on the disease phenotype. In addition, 
through single-cell gene expression and functional studies 
on HSCs from a JAK2V617F mouse model, he presented 
data on an HSC subpopulation with a self-renewal 
defective signature that can be partly restored in TET2/
JAKV617F double-mutant single cells, demonstrating that 
single-cell approaches are important to deconstruct the 
molecular network of normal and malignant stem cells 
[3]. The complexity underlying small cell lung cancer 
(SCLC) was covered by Dr. Caroline Dive (Manchester 
Cancer Research UK Center, Manchester, UK), who 
focused on Patient-Derived Xenografts (PDX) to study 
SCLC evolution, treatment response and resistance. SCLC 
presents early metastasis and poor prognosis and most 
patients have circulating tumor cells (CTCs) [4]. Through 
vasculogenic mimicry (VM), tumor cells may develop 
their own blood vessels endowing them with invasive and 
metastatic potential [5]. Clinically, VM could be targeted 
for therapeutic intervention in SCLC; however, how VM 
contributes to ITH and clonal diversification is still being 
unraveled. From a computational perspective, Dr. Núria 
López-Bigas (Institute of Biomedical Research, Barcelona, 
Spain) illustrated how cancer drivers may be identified 
from mutations coming from NGS in cohort studies. She 
described different bioinformatics tools and resources 
generated by her group (OncodriveFM, OncodriveROLE 
and OncodriveCLUST). She also introduced how to 
approach mutations in coding and non-coding regions, 
emphasizing the need to collect biomedical genomic data 
in the database IntOGen along with the Global Alliance 
for Genomics and Health. For localized tumors, she 
described Cancer Genome Interpreter, a platform that 
supports the identification of therapeutically actionable 
genomic alterations in tumors. Dr. Sean Bendall (Stanford 
University, CA, USA) presented data on mass cytometry 
as a novel and revolutionary high-throughout tool for 
single cell proteomics, permitting the examination of 
multiple parameters in normal human bone marrow or 
leukemic cells [6]. Using single-cell mass cytometry 
data analysis with an in-house designed algorithm 
(Wanderlust) he could produce trajectories predictive 
of the cellular developmental path in human B-cell 
lymphopoiesis [7]. He then presented how this can be 
used to identify developmentally dependent predictors of 
relapse in diagnostic B-cell precursor acute lymphoblastic 
leukemia. To close the session, Dr. Carlo Maley (Arizona 
State University, Tempe, USA) gave the keynote lecture 
and explained how resources and hazards in tumors select 
for cell migration and metastasis [8]. He formulated 
several open questions on cancer evolution such as how to 
better sample tumors, the relationship between evolution 
versus ecology index and the best predictor of mutation 
rate. He also introduced ideas about how to manage ITH 
and suggested an adaptive therapy for cancer treatment, 
whereby more proliferative but less aggressive clones 
are not completely eliminated and are used to keep more 
dangerous populations under control. This implies that 
after the induction phase of treatment, consolidation 
chemotherapy should be proportional to the tumor size, in 
an attempt to maintain the tumor at a stable size and not to 
completely eradicate it. Therefore, therapeutic strategies 
should evolve in response to tumor adaptation.
ITH IN HEMATOPOIETIC MALIGNANCIES
The session was dedicated to ITH in hematologic 
malignancies, with outstanding talks on the cell-of-origin 
and the genomic landscape of acute myeloid leukemia 
(AML) and chronic lymphocytic leukemia (CLL). Dr. 
John Dick (Sick Children’s Hospital at the University of 
Toronto, Canada) presented data on a 17-gene leukemia 
stem cell (LSC) core signature (LSC17) as an independent 
prognostic factor to predict survival in AML. The LSC17 
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signature allows for a better stratification of patients 
receiving induction therapy for whom relapse often occurs, 
and can be used in diagnosis risk-stratification in AML 
[9]. He also discussed the nature of the leukemia/relapse-
initiating cell in AML; the LSC at relapse can easily differ 
from that at diagnosis. Importantly, pre-leukemic HSCs 
carrying DNMT3A mutations can be found at diagnosis, 
even in the absence of the recurrent driver-initiating 
event, and be maintained at relapse. Finally, Dr. Dick 
described cases of clonal hematopoiesis of indeterminate 
potential either developing (AML+) or not developing 
(non AML) overt leukemia. He showed that these 
groups present different mutation types, and oncogenic 
mutations are found in cases of AML+. Focusing on 
genetic and phenotypic heterogeneity in AML, Dr. Elli 
Papaemmanuil (The Memorial Sloan Kettering Cancer 
Center in New York, USA) presented the revised genomic 
classification for AML based on cancer gene driver and 
passenger mutations, and reported the emergence of three 
novel heterogeneous genomic categories added to the 
pre-existing classifications: i) chromatin-spliceosome; 
ii) p53-aneuploidies; and iii) IDH2R172 mutations. Her 
lecture covered topics such as the mutation acquisition 
order, mutational co-occurrence, mutual exclusivity 
and deterministic nature of the mutations [10]. She also 
discussed how to implement precision medicine in AML 
patients based on banked genomic-clinical data [11]. 
Finally, Dr. Xosé Puente (University of Oviedo, Spain) 
provided insights into the genomic architecture of B-CLL. 
Mature B-cell and B-CLL integrative analysis, constructed 
with WGS and WES data, as well as RNA sequencing, 
copy number variation (CNV) and DNA methylation, 
revealed different B-CLL molecular signatures and 
provided evidence about recurrent and non-recurrent 
driver genes [12]. The majority of the genes were mutated 
at low frequency (sub-clonal), with the most common 
alterations affecting genes for immunoglobulins, DNA 
damage response, splicing, NF-kB and Notch pathways. 
Notably, the number of driver alterations correlated with 
patient clinical behavior. 
ITH IN SOLID TUMORS
Most ITH results have been acquired by the 
study of solid tumours. Dr. Mario Suvà (Massachusetts 
General Hospital and Harvard Medical School, Boston, 
USA) presented data on single-cell RNA-sequencing of 
oligodendrioglioma. Six patients were assessed and an in-
house written algorithm was used to infer CNV and tumor 
architecture. While most cancer cells seemed to have 
transcriptional signatures reminiscent of oligodendrocytes 
and astrocytes, a few cells within the bulk tumor showed 
a transcriptome profile resembling a neural stem cell 
phenotype and cell proliferation expression programs. 
These cancer stem cells would be responsible for fueling 
tumor growth [13]. Dr. Suvà also introduced single-cell 
analysis to comprehend the molecular differences between 
oligodendrioglioma and astrocytoma cancer cells. On 
the same topic of brain tumors with dismal prognosis, 
Dr. Chris Jones (Institute of Cancer Research, Sutton, 
UK) reported on pediatric high-grade diffuse intrinsic 
pontine glioma (DIPG). No pre-treatment material was 
available to study this subgroup until a sophisticated 
biopsy procedure was implemented some years ago. 
Molecular studies revealed that point mutations in several 
histone-coding genes define different clinical subgroups 
with different prognoses and phenotypes [14]. He also 
speculated on how cooperation between cancer subclones 
could promote infiltration, migration and invasion in 
DIPG. Dr. Marco Gerlinger (Institute of Cancer Research, 
Sutton, UK) discussed precision medicine in primary renal 
carcinoma. Multi-region genome and RNA-sequencing 
profiling revealed a branched evolution of the tumor, with 
an abundance of subclones with independent branching 
evolution [15]. He anticipated the difficulty to target 
subclonal somatic activating mutations of mTOR not 
present in the tumor trunk. He also presented data on 
ITH in gastro-oesophageal adenocarcinoma. Targeted 
sequencing studies revealed a median of three mutations/
patient and high chromosomal instability with copy 
number alterations (CNA) heterogeneous among the 
sequenced regions. Overall, he emphasized the complexity 
of the tumor genomic landscape and also the drawbacks 
of combined polytherapy to target multiple drivers. Dr. 
Peter Dirks (Sick Children’s Hospital, Toronto) discussed 
how quiescent Sox2+ cells drive hierarchical growth 
and relapse in a subgroup of sonic hedgehog-dependent 
medulloblastoma. He showed how drugs targeting this 
pathway, such as Smoothened inhibitors (SMOi), are 
ineffective because Sox2+ cells are resistant to SMOi, 
which only shrink the tumor bulk while leaving a 
reservoir of self-renewing cells responsible for relapse 
[16]. He also suggested that enforcing glioblastoma 
cells to neuronal lineage commitment would decrease 
ITH, a type of “differentiation therapy”. Dr. Joan Seoane 
(Vall d’Hebron Institute of Oncology, Barcelona, Spain) 
presented an update on research on glioblastoma, a 
brain tumor in which tumor DNA detection by liquid 
biopsy of cerebrospinal fluid (CSF) has been recently 
reported to be very informative for clinical interventions. 
He described a complex heterogeneity at the level of 
stromal cells, genome and epigenome. He reinforced the 
use of digital PCR to confirm sequencing results from 
longitudinal sampling, especially since many mutations 
found at relapse are commonly undetectable at diagnosis 
due to very low variant allele frequency. Dr. Alberto 
Bardelli (University of Torino, Italy) summarized data 
from the phase 2 clinical trial HERACLES, aimed at 
assessing dual-targeted therapy with trastuzumab and 
lapatinib in treatment-refractory HER2-positive metastatic 
colorectal cancer [17]. He also illustrated the advantages 
of transrenal DNA as a diagnostic tool to monitor MRD 
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and follow up cancer patients, and the need for new 
technologies to overcome DNA fragmentation upon 
infiltration. Finally, Dr. Eric Holland (Fred Hutchinson 
Cancer Research Center, Seattle, USA), presented how 
big data visualization identifies the multidimensional 
molecular landscape of human gliomas. His group found 
that CNV and single nucleotide alterations across the 
genome are quite different, generating three main glioma 
clusters [18]. He also introduced Oncospace, an open 
source application for disease data sets across multiple 
cancer types, which allows researchers to discover novel 
patterns and relationships between clinical and molecular 
data.
DEALING WITH ITH IN THE CLINICAL 
PRACTICE
The meeting ended with a roundtable discussion 
between speakers and the audience moderated by Dr. 
Josep Tabernero (Vall d’Hebrón Institute of Oncology, 
Barcelona, Spain). The benefit of liquid biopsy as a 
surrogate diagnostic tool when tumor biopsy is not 
accessible was discussed. Liquid biopsies can retrieve 
either plasma cell-free circulating DNA (cfDNA) or 
CTCs [19]. cfDNA can be used to quantify tumor burden, 
and cfDNA in blood or CSF can be sequenced since 
its mutational spectrum frequently mirrors that of the 
tumor of origin. However, it is uncertain whether liquid 
biopsies phenocopy the malignant phenotype and more 
investigation is needed to evaluate this. Although attempts 
to translate the value of cfDNA to the clinical setting are 
ongoing, the use of liquid biopsies in the clinics awaits 
approval from regulatory bodies. 
The presence of co-existing diverse sub-clones 
carrying different driver and passenger mutations makes 
the treatment selection process difficult. Polytherapy can 
exhaust patients due to excessive adverse effects, and 
access to new drugs is occasionally delayed by approval 
and reimbursement bodies. In the setting of pediatric 
tumors, pediatric oncologists employ therapeutic drugs 
designed for adults in children but these are not effective. 
Therefore, oncologists managing neuroectodermal/
brain tumors claim the need to think more outside the 
box. Thinking from a new perspective is necessary for 
clinicians to introduce new drugs into clinical trials and to 
explore risky and new treatments.
Finally, the need for crosstalk between researchers 
and physicians was highlighted. The feeling was that 
there is a lack of communication to translate laboratory 
research to clinical practice and vice versa. How would it 
be possible to establish a researcher-physician interaction 
model? Apart from thinking differently, the main demand 
was the usage of public resources to share genomic and 
clinical data. 
CONCLUDING REMARKS
ITH is a major factor contributing to cancer 
outcome, therapeutic failure and drug resistance. 
Importantly, ITH does not simply reflect genomic diversity 
but also variation in epigenetic mechanisms and tumor 
microenvironment. In spite of recent advances in the ITH 
field, such as MRS, liquid biopsies, single-cell approaches, 
increased depth and purity of sequenced material and more 
sophisticated bioinformatics tools, many key questions 
remain. For example, the impact of mutations occurring 
in non-coding regions, the accuracy of evolutionary 
trajectories reconstructed from genomic data modeling 
without considering epigenomic and microenvironmental 
components, the mechanisms of tumor cells to evade the 
immune system and the viability of precision medicine 
based on individual genomic make-up in the clinical 
practice. In this regard, cancer evolutionary therapeutics 
has only just begun [20] started. Recommendations for 
future research are to better explore the temporal and 
spatial dynamics of clones in human tumors. Also, the use 
of computational, pathological and imaging approaches 
to better describe the tumor microenvironment is in high 
demand. In the interest of the patients, these tools should 
be easily implemented in the clinics. Finally, current 
educational programs on in silico biology should be 
offered to oncology trainees. Understanding the dynamic 
evolution of tumors is fundamental for drug development 
and novel clinical trial designs. 
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